## **Modeling from the margins to the masses:** Perspectives on commercial tobacco and health equity

March 3<sup>rd</sup>, 2023 SRNT 2023 - San Antonio, TX

Jamie Tam, MPH, PhD Assistant Professor Department of Health Policy and Management

Yale school of public health

#### Disclosures

No conflicts of interest to disclose.

1

#### <u>Land</u>

- New Haven exists on Wappinger, Quinnipiac, Paugussett land
- San Antonio exists on Tonkawa, Coahuiltecan, Jumanos, Ndé Kónitsąąíí Gokíyaa (Lipan Apache) land

#### <u>Funding</u>

2

- F31 DA041083, K01 DA056424 (NIDA)e
- U01 CA253858, U01 CA199284 (NCI) CISNET
- U54 CA229974 (NCI) TCORS / CAsToR
- The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

#### Tobacco simulation models and health equity

- Monitor and forecast trends in commercial tobacco use disparities over time
- Evaluate and compare `what-if' intervention scenarios and their short and long-term impacts
- Investigate underlying dynamics that influence disparities
- Identify intervention strategies that have the greatest potential to achieve health equity goals



### Health equity objectives

- 1. WHO: "the absence of unfair and avoidable or remediable differences in health among population groups defined socially, economically, demographically or geographically"
- 2. Healthy People 2030: "the attainment of the highest level of health for all people"
- 3. "efforts to impact the determinants of health, reduce health disparities, and work toward health equity cannot fully be understood without the use of metrics. Measurement can also offer indication of what interventions best address disparities, their determinants, and ultimately impact progress toward equity."

- 1. Reduce health inequities between the most and least harmed
- 2. Maximize the health of groups disproportionately harmed
- 3. Build data infrastructure to monitor health equity progress

#### 1. Reduce inequities between the most and least harmed

- People with Serious Psychological Distress (SPD) comprise 3.7% of the US adult population
  - Kessler-6 item scale screens for serious mental illness in general population
    - Scores  $\geq 13 = SPD$
    - Scores <13 = No SPD.
- Current smoking by SPD status

2021	Total	SPD	No SPD	
Men	13.1%	32.5%	12.6%	
Women	10.1%	15.7%	9.3%	

## Life expectancy reduction by smoking and SPD status at age 40



5 National Health Interview Survey (NHIS)

Tam J, Warner KE, Meza R. Smoking and the Reduced Life Expectancy of Individuals With Serious Mental Illness. Am J Prev Med. 2016;51(6):958-966. doi:10.1016/j.amepre.2016.06.007.

### Modeling smoking among people with and without SPD



Smoking-attributable deaths ٠

6

$$= \sum_{a,g} P\left(prev_{cs} \times (\mu_{cs} - \mu_{ns}) + prev_{fs} \times (\mu_{fs} - \mu_{ns})\right)$$

• Years of life lost =  $(e_{ns,a,g} \times SAD_{a,g})$ .

- Populations modeled separately based on proportion with and without SPD by gender and age group in NHIS
- Dynamics of psychological distress not modeled
- CISNET annual initiation and cessation probabilities by age, gender, birth cohort

Calibrated for the SPD population

Xi Q, Meza R, Leventhal A, Tam J. Modeling cigarette smoking disparities between people with and without serious psychological distress in the US, 1997-2100. Prev Med. 2023;166:107385. doi:https://doi.org/10.1016/j.ypmed.2022.107385.

# Smoking among people with and without serious psychological distress (SPD)



7 Calibrated to NHIS 1997-2018; NHIS did not collect SPD data in 2019-2020.

# How will smoking disparities by SPD status change over time?

Smoking disc	parity measures	for adults with an	d without serious p	sychological distress	. Status Quo scenario	. 2023-2100

	Year		2023	2040	2060	2080	2100	Change from
			2023 2010	2000	2000	2100	2023-2100	
	SPD smoking prevalence		27.0%	17.0%	12.0%	10.9%	10.7%	-60%
	Non-SPD smo	king prevalence	9.4%	5.4%	3.6%	3.2%	3.1%	-67%
Women		Absolute difference	17.6%	11.6%	8.4%	7.7%	7.6%	
		Relative difference	1.9	2.1	2.3	2.4	2.5	
		Prevalence ratio	2.9	3.1	3.3	3.4	3.5	
	SPD smoking	prevalence	30.1%	18.7%	13.6%	12.5%	12.2%	-59%
	Non-SPD smoking prevalence		11.5%	6.3%	4.5%	4.1%	4.0%	-65%
								_
Nen		Absolute difference	18.2%	12.0%	9.6%	8.4%	7.6%	
		Relative difference	1.6	2.0	2.0	2.0	2.1	
		Prevalence ratio	2.6	3.0	3.0	3.0	3.1	

#### 1. Reduce inequities between the most and least harmed

- Whether smoking-related disparities will improve or worsen over time depends on what type of metric is used
  - Absolute metrics: overall population trends
  - Relative metrics: fairness as principle
- Health equity, in relative terms, is a moving target if advantaged groups continue to benefit from tobacco control progress
- Both absolute and relative metrics should be used

<sup>9</sup> Identifying and Eliminating Tobacco-Related Disparities: Key Outcome Indicators for Evaluating Comprehensive Tobacco Control Programs—2022, 2021. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.

### 2. Maximize the health of groups disproportionately harmed

- Maximum Potential Reduction in Premature Mortality (MPRPM)
  - All individuals who smoke immediately quit in 2024
  - $_{\circ}$  No new smoking initiation occurs from 2023 to 2100.

## What is the relative contribution of prevention vs cessation to the MPRPM?

- No Initiation
  - $_{\circ}\,$  No new smoking initiation occurs from 2023 to 2100
  - Cessation rates remain unchanged
- Complete Cessation = MPRPM No Initiation

<sup>10</sup> Warner KE, Mendez D. How much of the future mortality toll of smoking can be avoided? *Tob Control.* 2020:tobaccocontrol-2019-055530. doi:10.1136/tobaccocontrol-2019-055530.

# Smoking among people with and without serious psychological distress (SPD)



Calibrated to NHIS 1997-2018; NHIS did not collect SPD data in 2019-2020.

# Smoking among people with and without serious psychological distress (SPD)



Calibrated to NHIS 1997-2018; NHIS did not collect SPD data in 2019-2020.

#### The impact of cessation on mortality reductions

SPD	Cumulative premature deaths averted				Cumulative life-years gained					
Year	No- Initiation scenario	MPRPM scenario	Difference (Complete cessation)	No- Initiation as % of MPRPM	Complete Cessation as % of MPRPM	No- Initiation scenario	MPRPM scenario	Difference (Complete cessation)	No- Initiation as % of MPRPM	Complete Cessation as % of MPRPM
2030	0	22,209	22,209	0.0%	100.0%	0	300,086	300,086	0.0%	100.0%
2040	1	79,510	79,509	0.0%	100.0%	11	1,151,416	1,151,405	0.0%	100.0%
2050	20	152,795	152,775	0.0%	100.0%	371	2,121,556	2,121,185	0.0%	100.0%
2060	843	221,366	220,523	0.4%	99.6%	19,713	2,949,742	2,930,029	0.7%	99.3%
2070	6,531	275,751	269,220	2.4%	97.6%	140,960	3,584,136	3,443,176	3.9%	96.1%
2080	21,484	318,331	296,847	6.8%	93.3%	432,082	4,088,688	3,656,606	10.6%	89.4%
2090	43,066	353,509	310,443	12.2%	87.8%	797,883	4,527,661	3,729,778	17.6%	82.4%
2100	69,868	385,513	315,645	18.1%	81.9%	1,178,656	4,927,790	3,749,134	23.9%	76.1%

### Smoking among people with major depressive episodes

- 8.4% of US adults with Current Major Depressive Episode (MDE)
  - 21.0 million adults
  - Men: 6.1%

14

- Women: 10.5%
- MDE = 2 week+ period during which the respondent reports experiencing at least 5 of 9 symptoms (DSM-IV/5) in the past year
  - No exclusions due to illness, mourning, substance use disorders, or other psychiatric disorder

 Past 30-day cigarette smoking prevalence by MDE status

2020	Total, Ages 18+	Current MDE	Never MDE
Men	17.5%	24.4%	16.7%
Women	14.6%	22.4%	12.6%

- Most public and private mental health settings do not offer smoking cessation treatment
  - 37.6% report offering cessation counseling
  - 。 25.2% report offering NRT

- Systematic review of cessation treatment RCTs among patients with MD evaluated long-term cessation:
  - Pharmacological Treatment Risk Ratio = 1.588 (95% CI: 1.230-2.049)
  - Varenicline, nicotine gum, fluoxetine, bupropion, nicotine patch
- Evaluate and quantify the potential missed opportunity for tobacco control by modeling `what if' scenarios:
  - Cessation treatment used by all patients in mental health settings?
  - Increased mental health service and cessation treatment utilization?
  - Cessation treatments became more effective?
- Compare best case 'treatment' scenarios with best case 'cessation' scenario

   Maximum Potential Cessation (MPC) scenario

Secades-Villa R, et al. Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: A systematic review and meta-analysis. *PLoS One.* 2017;12(12):e0188849.

#### Model development and calibration



#### Major Depression and Smoking (MDS) model



, Tam J, Taylor GMJ, Zivin K, Warner KE, Meza R. Modeling smoking-attributable mortality among adults with major depression in the United States. Prev Med. 2020:106241. doi:10.1016/j.ypmed.2020.106241.

#### Yale SCHOOL OF PUBLIC HEALTH

17

#### Model projections under baseline scenario



#### Current smoking is defined as smoking at all within the past year and smoking at least 100 lifetime cigarettes. This models permanent smoking cessation and accounts for high rates of relapse within the first year of quitting. Model calibrated to NSDUH 2005-2019 data.

#### Model projections under baseline scenario, No MDE increase



Current smoking is defined as smoking at all within the past year and smoking at least 100 lifetime cigarettes. This models permanent smoking cessation and accounts for high rates of relapse within the first year of quitting. Model calibrated to NSDUH 2005-2019 data.

#### MDS model with intervention



#### Mental health service utilization = Proportion of current smoking adults with MDEs

who self-report seeing a health professional for their depression

Age group	Women	Men
18-25	49.6%	37.5%
26-34	62.3%	44.8%
35-49	70.7%	54.1%
50-64	73.3%	66.1%
65+	67.6%	59.0%
Total	65.8%	51.3%

Tam J, Warner KE, Zivin K, Taylor GMJ, Meza R. The Potential Impact of Widespread Cessation Treatment for Smokers With Depression. *Am J Prev Med*. 2021;61(5):674-682.

#### Intervention scenarios, 2024-2100



Current smoking is defined as smoking at all within the past year and smoking at least 100 lifetime cigarettes. This models permanent smoking cessation and accounts for high rates of relapse within the first year of quitting. Model calibrated to NSDUH 2005-2019 data.

#### Intervention outcomes for adults with MDEs, 2024-2100

effectiveness

2024-2100		Cessation treatment intervention (% of MPC)						
	Mental health service utilization	Pharm Tx (58.8% increase)	100% increase	150% increase	200% increase	MPC		
Premature	No change from baseline	98 (19.2%)	150 (29.4%)	200 (39.2%)	239 (47%)	509		
deaths avoided	Increase by 10%	106 (19.7%)	161 (30.1%)	215 (40.1%)	257 (48%)	534		
(thousands)	Increase by 20%	115 (20.4%)	175 (31.1%)	232 (41.3%)	277 (49.3%)	562		
·	100%	158 (23.9%)	237 (35.9%)	310 (46.9%)	365 (55.2%)	662		
Life years	No change from baseline	0.4 (18.7%)	0.7 (28.8%)	0.9 (38.5%)	1.1 (46.2%)	2.3		
gained ( <i>millions</i> )	Increase by 10%	0.5 (19.2%)	0.7 (29.4%)	1 (39.3%)	1.2 (47.1%)	2.5		
	Increase by 20%	0.5 (19.8%)	0.8 (30.2%)	1 (40.3%)	1.2 (48.2%)	2.6		
	100%	0.7 (23.2%)	1.1 (34.9%)	1.4 (45.7%)	1.7 (54%)	3.1		

E-cig vs NRT for cessation: RR=1.63 (1.30-2.04)

#### Hartmann-Boyce J, Lindson N, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews. 2022(9). doi:10.1002/14651858.CD010216.pub7.

Yale SCHOOL OF PUBLIC HEALTH

uptake

### 2. Maximize the health of groups disproportionately harmed

- Cessation improvements achieve largest health gains compared to initiation
- Smoking projections influenced by underlying dynamics in populations of interest
  - Unclear whether rising MDEs among young adults are period vs cohort effects
- Health gains from cessation treatments are modest even under highly optimistic conditions
  - Providing cessation treatment to patients with MDEs would reduce smokingrelated mortality
  - But cessation treatments need to be much more effective
- Bolder strategies are needed to complement treatment interventions
  - Pharmacological interventions are necessary but not sufficient to achieve health equity goals

#### 3. Build data infrastructure to monitor health equity progress

- Smoking prevalence alone is not the most informative
  - Comprised of distinct behaviors addressed through different intervention strategies:
  - Initiation, cessation, smoking intensity, transition behaviors
- Changing patterns by birth cohort are essential to understand both past and future
- Detailed data necessary for population models of disparate groups are often lacking
- Cancer Intervention and Surveillance Modeling Network (CISNET) age, period, and cohort analyses generates detailed smoking histories used in many tobacco simulation models

#### Age-Period-Cohort Analyses

- NHIS 1965-2018
- APC logistic regression models
- Temporal APC effects modeled using constrained natural splines
- Smoking initiation, cessation, intensity, prevalence, duration by age, year, gender, and birth cohort
- Parameters ready-for-use as inputs to simulation models



Yale school of public health

# Extensions of the Age-Period-Cohort Framework for US Population Smoking Histories



Tam J, Levy DT, Feuer EJ, Jeon J, Holford TR, Meza R. Using the Past to Understand the Future for US and Global Smoking Disparities: A Birth Cohort Perspective. *Am J Prev Med.* 2023;In press. **apps.cisnetsmokingparameters.org** 



#### Race/Ethnicity





#### • NHIS 1965-2018

- $_{\circ}\,$  Age effects for ever smoking
- TUS-CPS 1992-2019
  - Variation in smoking histories
     by state



<sup>27</sup> Meza R, Cao P, Jeon J, et al. Patterns of Birth Cohort-Specific Smoking Histories by Race and Ethnicity in the US. *Am J Prev Med.* 2023; In press. **apps.cisnetsmokingparameters.org/race/**  Holford TR, McKay L, Jeon J, et al. Smoking Histories by State in the US. *Am J Prev Med*. 2023;In press. **apps.cisnetsmokingparameters.org/states** 



#### Educational attainment

#### Family income



Cao P, Jeon J, Tam J, et al. Smoking Disparities by Level of Educational Attainment and Birth Cohort in the US. *Am J Prev Med.* 2023;In press. apps.cisnetsmokingparameters.org/education/

Jeon J, Cao P, Fleischer NL, et al. Birth Cohort-Specific Smoking Patterns by Family Income in the US. *Am J Prev Med.* 2023;In press.

apps.cisnetsmokingparameters.org/income/



#### **Global Disparities**





#### Research and policy planning strategy



30 Levy DT, Tam J, Jeon J, Holford TR, Fleischer N, Meza R. Summary and Concluding Remarks: Patterns of Birth Cohort–Specific Smoking Histories. Am J Prev Med. 2023;In press.

#### 3. Build data infrastructure to monitor health equity progress

- Surveillance and data infrastructure deficits hinder health equity research and policy progress
- Smoking parameters will soon be publicly available for download at <u>apps.cisnetsmokingparameters.org</u>
- Detailed cohort-specific inputs can support modeling research for priority populations
- Opportunities for APC framework to be extended to other countries with limited data

• E-cigarette use in models by mental health status

#### Looking Ahead

 Higher e-cig and dual use among people with MDEs and SPD





85.3

3.2

10.2

1.3

Total

- E-cigarette use in models by mental health status
- E-cigarette and cigar use by race/ethnicity, education
- COVID-19 impacts on tobacco use behaviors
- Reduced nicotine cigarette policy and implications for health equity
- Extend models to include morbidity and economic outcomes
- Model diverse populations as the rule, not the exception
- Health equity as the tobacco endgame

### **CISNET Supplement Authors**

- Pianpian Cao
- Maki Inoue-Choi
- Eric 'Rocky' J Feuer
- Nancy L Fleischer
- Neal D Freedman
- Theodore R Holford
- Mohammed A Jaffri
- Jihyoun Jeon

- David T Levy
- Lisa McKay
- Timothy S McNee
- Rafael Meza
- Yoonseo Mok
- Luz Maria Sanchez-Romero
- Miriam C Souza
- André S Szklo



**APT** 

#### Thank You

#### Mentors & Collaborators

- Rafael Meza
- Ken Warner
- Jihyoun Jeon
- Ted Holford
- David Levy
- David Fiellin
- Abby Friedman
- Susan Busch
- Kara Zivin
- Peter Jacobson
- CAsToR & CISNET colleagues
- Friends at CTP
- and many, many more ...

#### Support & Community

- Matty
- Chosen Family
- Tamily